{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:56:41Z","timestamp":1781053001922,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NTNU Norwegian University of Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Several reports have indicated an association between insulin resistance and hyperferritinemia, and a recent consensus statement has suggested the term metabolic hyperferritinemia (MHF) for patients with metabolic syndrome and increased serum ferritin. The objective of this study was to examine the association between serum ferritin levels and insulin resistance in an unselected Norwegian population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two thousand people were randomly selected from the public registry in one municipality in Nord-Tr\u00f8ndelag County, Norway. Of the respondents, 1115 completed a screening glucose tolerance test to determine the prevalence of impaired glucose tolerance (IGT)\/type 2 diabetes mellitus (T2DM), and these individuals were then selected for further examination. A control group comprising 100 age- and gender-matched individuals with normal glucose tolerance and CRP less than 5 was retrospectively generated from the same cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and seventy-six people were diagnosed with impaired glucose tolerance or diabetes mellitus type 2 (IGT\/T2DM), and 17 (10%) of these patients had elevated ferritin levels according to the MHF definition. In the control group with normal glucose tolerance, 11% also had hyperferritinemia based on the same ferritin cut-off. Multiple regression revealed a significant association between serum ferritin, male sex, 2-hour glucose value after the glucose load and waist circumference among the patients with IGT\/T2DM, while there was no association with age or transferrin saturation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated a prevalence of metabolic hyperferritinemia in one out of ten people with IGT\/T2DM; however, a comparable level of serum ferritin was also detected in the matched control group. Only one person in the IGT\/T2DM group had ferritin levels higher than 550 mmol\/L. Thus, hyperferritinemia is prevalent in this unselected Norwegian cohort. A relationship between s-ferritin and metabolic syndrome parameters was found in patients with IGT\/T2DM, but hyperferritinemia is likely not related to iron overload.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-026-02161-9","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:35:04Z","timestamp":1777113304000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of metabolic hyperferritinemia and association between ferritin and insulin resistance in persons with impaired glucose regulation in the HUNT2 population study"],"prefix":"10.1186","volume":"18","author":[{"given":"Kristoffer","family":"Sand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Brudevold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torstein","family":"Hole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"1","key":"2161_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0025-6196(12)61605-X","volume":"69","author":"SF Dinneen","year":"1994","unstructured":"Dinneen SF, Silverberg JD, Batts KP, O\u2019Brien PC, Ballard DJ, Rizza RA. Liver iron stores in patients with non-insulin-dependent diabetes mellitus. Mayo Clin Proc. 1994;69(1):13\u20135.","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"2161_CR2","doi-asserted-by":"publisher","first-page":"540","DOI":"10.5604\/16652681.1202947","volume":"15","author":"A Castiella","year":"2016","unstructured":"Castiella A, Zapata E, Zubiaurre L, et al. Liver iron concentration is not raised in patients with dysmetabolic hyperferritinemia. Ann Hepatol Jun 1. 2016;15(4):540\u20134. https:\/\/doi.org\/10.5604\/16652681.1202947.","journal-title":"Ann Hepatol Jun 1"},{"issue":"2","key":"2161_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00592-014-0646-3","volume":"52","author":"N Wlazlo","year":"2015","unstructured":"Wlazlo N, van Greevenbroek MM, Ferreira I, et al. Iron metabolism is prospectively associated with insulin resistance and glucose intolerance over a 7-year follow-up period: the CODAM study. Acta Diabetol. 2015;52(2):337\u201348. https:\/\/doi.org\/10.1007\/s00592-014-0646-3.","journal-title":"Acta Diabetol"},{"issue":"5","key":"2161_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41574-023-00807-6","volume":"19","author":"L Valenti","year":"2023","unstructured":"Valenti L, Corradini E, Adams LA, et al. Consensus statement on the definition and classification of metabolic hyperferritinaemia. Nat Rev Endocrinol. 2023;19(5):299\u2013310. https:\/\/doi.org\/10.1038\/s41574-023-00807-6.","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"2161_CR5","doi-asserted-by":"publisher","first-page":"e105610","DOI":"10.1371\/journal.pone.0105610","volume":"9","author":"G Tarantino","year":"2014","unstructured":"Tarantino G, Costantini S, Finelli C, et al. Carotid intima-media thickness is predicted by combined eotaxin levels and severity of hepatic steatosis at ultrasonography in obese patients with Nonalcoholic Fatty Liver Disease. PLoS ONE. 2014;9(9):e105610. https:\/\/doi.org\/10.1371\/journal.pone.0105610.","journal-title":"PLoS ONE"},{"key":"2161_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050842","author":"NA Anastasopoulos","year":"2025","unstructured":"Anastasopoulos NA, Barbouti A, Goussia AC, Christodoulou DK, Glantzounis GK. Exploring the Role of Metabolic Hyperferritinaemia (MHF) in Steatotic Liver Disease (SLD) and Hepatocellular Carcinoma (HCC). Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17050842.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2161_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-14-483","volume":"14","author":"V Abril-Ulloa","year":"2014","unstructured":"Abril-Ulloa V, Flores-Mateo G, Sola-Alberich R, Manuel-y-Keenoy B, Arija V. Ferritin levels and risk of metabolic syndrome: meta-analysis of observational studies. BMC Public Health. 2014;14(1):483. https:\/\/doi.org\/10.1186\/1471-2458-14-483.","journal-title":"BMC Public Health"},{"issue":"3","key":"2161_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2337\/diacare.20.3.426","volume":"20","author":"TP Tuomainen","year":"1997","unstructured":"Tuomainen TP, Nyyssonen K, Salonen R, et al. Body iron stores are associated with serum insulin and blood glucose concentrations. Population study in 1,013 eastern Finnish men. Diabetes Care. 1997;20(3):426\u20138.","journal-title":"Diabetes Care"},{"issue":"2","key":"2161_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1530\/eje.1.02083","volume":"154","author":"CE Wrede","year":"2006","unstructured":"Wrede CE, Buettner R, Bollheimer LC, Scholmerich J, Palitzsch KD, Hellerbrand C. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur J Endocrinol. 2006;154(2):333\u201340. https:\/\/doi.org\/10.1530\/eje.1.02083.","journal-title":"Eur J Endocrinol"},{"key":"2161_CR10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad749","author":"WY Liu","year":"2023","unstructured":"Liu WY, Lian LY, Zhang H, et al. A Population-based and Clinical Cohort Validation of the Novel Consensus Definition of Metabolic Hyperferritinemia. J Clin Endocrinol Metab. 2023. https:\/\/doi.org\/10.1210\/clinem\/dgad749.","journal-title":"J Clin Endocrinol Metab"},{"key":"2161_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010207","author":"S Gensluckner","year":"2024","unstructured":"Gensluckner S, Wernly B, Koutny F, et al. Prevalence and Characteristics of Metabolic Hyperferritinemia in a Population-Based Central-European Cohort. Biomedicines. 2024. https:\/\/doi.org\/10.3390\/biomedicines12010207.","journal-title":"Biomedicines"},{"key":"2161_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61091518","author":"S Cernea","year":"2025","unstructured":"Cernea S, Roiban AL, Onisor D. Hyperferritinemia and the Risk of Liver Fibrosis and Liver-Related Events in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease. Medicina (Kaunas). 2025. https:\/\/doi.org\/10.3390\/medicina61091518.","journal-title":"Medicina (Kaunas)"},{"issue":"1","key":"2161_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyac095","volume":"52","author":"BO Asvold","year":"2023","unstructured":"Asvold BO, Langhammer A, Rehn TA, et al. Cohort profile update: The HUNT study, Norway. Int J Epidemiol. 2023;52(1):e80. https:\/\/doi.org\/10.1093\/ije\/dyac095.","journal-title":"Int J Epidemiol"},{"key":"2161_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyae073","author":"M Naess","year":"2024","unstructured":"Naess M, Kvaloy K, Sorgjerd EP, et al. Data Resource Profile: The HUNT Biobank. Int J Epidemiol. 2024. https:\/\/doi.org\/10.1093\/ije\/dyae073.","journal-title":"Int J Epidemiol"},{"issue":"11","key":"2161_CR15","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.2337\/diacare.22.11.1813","volume":"22","author":"K Midthjell","year":"1999","unstructured":"Midthjell K, Kruger O, Holmen J, et al. Rapid changes in the prevalence of obesity and known diabetes in an adult Norwegian population. The Nord-Trondelag Health Surveys: 1984\u20131986 and 1995\u20131997. Diabetes Care Nov. 1999;22(11):1813\u201320. https:\/\/doi.org\/10.2337\/diacare.22.11.1813.","journal-title":"Diabetes Care Nov"},{"issue":"1","key":"2161_CR16","first-page":"19","volume":"13","author":"JM Holmen","year":"2003","unstructured":"Holmen JM, Kr\u00fcger K, Langhammer \u00d8, Holmen A, Bratberg TL, Vatten GH, et al. The Nord-Tr\u00f8ndelag Health Study 1995-97 (HUNT 2): Objectives, contents, methods and participation. Norsk Epidemiol. 2003;13(1):19\u201332.","journal-title":"Norsk Epidemiol"},{"key":"2161_CR17","unstructured":"WHO. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. 1999."},{"issue":"1","key":"2161_CR18","doi-asserted-by":"publisher","first-page":"10232","DOI":"10.3402\/vgi.v3i0.10232","volume":"3","author":"E Hansen","year":"2012","unstructured":"Hansen E, Landstad BJ, Gundersen KT, Svebak S. The relative importance of aerobic capacity, physical activity and body mass index in impaired glucose tolerance and Type 2 diabetes. Vulnerable Groups Inclusion. 2012;3(1):10232. https:\/\/doi.org\/10.3402\/vgi.v3i0.10232.","journal-title":"Vulnerable Groups Inclusion"},{"issue":"10","key":"2161_CR19","doi-asserted-by":"publisher","first-page":"e3547","DOI":"10.1371\/journal.pone.0003547","volume":"3","author":"R Brudevold","year":"2008","unstructured":"Brudevold R, Hole T, Hammerstrom J. Hyperferritinemia is associated with insulin resistance and fatty liver in patients without iron overload. PLoS ONE. 2008;3(10):e3547. https:\/\/doi.org\/10.1371\/journal.pone.0003547.","journal-title":"PLoS ONE"},{"issue":"9045","key":"2161_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0140-6736(96)06034-5","volume":"11","author":"R Moirand","year":"1997","unstructured":"Moirand R, Mortaji AM, Loreal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet Jan. 1997;11(9045):95\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(96)06034-5.","journal-title":"Lancet Jan"},{"issue":"2","key":"2161_CR21","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00277-010-1050-x","volume":"90","author":"LY Chen","year":"2011","unstructured":"Chen LY, Chang SD, Sreenivasan GM, et al. Dysmetabolic hyperferritinemia is associated with normal transferrin saturation, mild hepatic iron overload, and elevated hepcidin. Ann Hematol Feb. 2011;90(2):139\u201343. https:\/\/doi.org\/10.1007\/s00277-010-1050-x.","journal-title":"Ann Hematol Feb"},{"issue":"9491","key":"2161_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","volume":"24\u201330","author":"KG Alberti","year":"2005","unstructured":"Alberti KG, Zimmet P, Shaw J, Group IDFETFC. The metabolic syndrome\u2013a new worldwide definition. Lancet. Sep 2005;24\u201330(9491):1059\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(05)67402-8.","journal-title":"Lancet"},{"key":"2161_CR23","unstructured":"WHO. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. 2020. WHO Guidelines Approved by the Guidelines Review Committee."},{"issue":"7","key":"2161_CR24","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1182\/blood-2007-07-102673","volume":"1","author":"J Waalen","year":"2008","unstructured":"Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferritin levels: a more effective approach. Blood Apr. 2008;1(7):3373\u20136. https:\/\/doi.org\/10.1182\/blood-2007-07-102673.","journal-title":"Blood Apr"},{"issue":"3","key":"2161_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41418-022-00941-0","volume":"29","author":"J Chen","year":"2022","unstructured":"Chen J, Li X, Ge C, Min J, Wang F. The multifaceted role of ferroptosis in liver disease. Cell Death Differ Mar. 2022;29(3):467\u201380. https:\/\/doi.org\/10.1038\/s41418-022-00941-0.","journal-title":"Cell Death Differ Mar"},{"issue":"3","key":"2161_CR26","doi-asserted-by":"publisher","first-page":"E30","DOI":"10.1111\/hepr.12921","volume":"48","author":"AR Murali","year":"2018","unstructured":"Murali AR, Gupta A, Brown K. Systematic review and meta-analysis to determine the impact of iron depletion in dysmetabolic iron overload syndrome and non-alcoholic fatty liver disease. Hepatol Res Feb. 2018;48(3):E30\u201341. https:\/\/doi.org\/10.1111\/hepr.12921.","journal-title":"Hepatol Res Feb"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02161-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02161-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02161-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:58:26Z","timestamp":1781049506000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-026-02161-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2161"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02161-9","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Ethics Board (REK) under application numbers 152\/95\/AH\/JGE, 4.2006.250 and 881426 under concession number 15\/01521-11\/GRA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}